Answers are grounded in this paper and cite their sources.
ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.
No takes yet. Share an insight, caveat, or question.
Corey R. Hopkins (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: